Related Experiment Video

Updated: Jun 16, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Novel agents for B-cell non-Hodgkin lymphoma: science and the promise

Kevin Tay1, Kieron Dunleavy, Wyndham H Wilson

  • 1Center for Cancer Research, National Cancer Institute, National Institutes of Health, 10 Centre Drive, Bethesda, MD 20892-1203, USA.

Blood Reviews
|February 16, 2010
PubMed

Insights

Novel therapies for non-Hodgkin lymphoma are emerging from basic science research. This review covers new immunotherapies and small molecule drugs targeting key cancer pathways.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Recent advances in basic science research have identified new molecular targets in neoplastic cells.
  • These discoveries provide a foundation for developing novel therapeutic agents for non-Hodgkin lymphoma (NHL).

Purpose of the Study:

  • To review novel therapeutic agents and treatment strategies currently under investigation for non-Hodgkin lymphoma.
  • To categorize these agents based on their mechanisms of action and therapeutic approach.

Main Methods:

  • Literature review of recent scientific publications and clinical trial data.
  • Categorization of novel agents into immunotherapy and small molecule inhibitors.
  • Analysis of anti-tumor mechanisms including apoptosis, proteasome inhibition, mTOR, CDK, and HDAC inhibition.

Main Results:

  • Novel agents are broadly classified into immunotherapies (monoclonal antibodies, immunomodulators) and small molecule inhibitors.
  • These agents target critical pathways involved in tumorigenesis, such as apoptosis, proteasomes, mTOR, CDKs, and HDACs.
  • Various treatment approaches utilizing these novel agents are currently in clinical evaluation for NHL.

Conclusions:

  • Emerging novel agents show promise for the treatment of non-Hodgkin lymphoma.
  • Targeted therapies and immunotherapies represent a significant advancement in NHL treatment strategies.
  • Ongoing clinical evaluations are crucial for establishing the efficacy and safety of these new treatments.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions08:17

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on: September 12, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...